adezmapimod Search Results


hy 10256 sb239063 medchemexpress  (MedChemExpress)
96
MedChemExpress hy 10256 sb239063 medchemexpress
Hy 10256 Sb239063 Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy 10256 sb239063 medchemexpress/product/MedChemExpress
Average 96 stars, based on 1 article reviews
hy 10256 sb239063 medchemexpress - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
sb203580  (TargetMol)
94
TargetMol sb203580
Clemastine improves axonal hypomyelination via inhibition of <t>p38</t> phosphorylation in microglial cells. Panel a showing phosphorylation-p38 (38 kDa) and total-p38 (38 kDa) immunoreactive bands. Panel b is bar graph which indicates that expression of p-p38 were improved in the AMCs after OGD administration for 1 h. The clemastine and MCC950 may attenuate the increment. Panel c showing IL-1β (17 kDa), NLRP3 (62 kDa), and β-actin (42 kDa) immunoreactive bands. Panels d and e are bar graphs showing the expression of IL-1β and NLRP3 were significantly up-regulated at 1 h after treatment with OGD compared with the controls. Clemastine could reduce the high expressions of NLRP3 and IL-1β proteins by inhibiting the p-p38. The inhibition was strengthened after adding additional MCC950 or <t>SB203580</t> (a specific p38 pathway inhibitor). Panel f showing MBP (32 kDa), CNPase (48 kDa), and β-actin (42 kDa) immunoreactive bands. Panels h and g are bar graphs showing the protein expressions of MBP and CNPase were significantly downregulated at 7 days after OGD compared with the controls. Clemastine and SB203580 could upregulate the expressions of MBP and CNPase proteins induced by OGD by inhibiting the p-p38. When additional MCC950 or SB203580 was added, the expression of MBP was upregulated compared with the OGD + clemastine group. N =3. * P < 0.05
Sb203580, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sb203580/product/TargetMol
Average 94 stars, based on 1 article reviews
sb203580 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
adezmapimod hydrochloride  (MedChemExpress)
95
MedChemExpress adezmapimod hydrochloride
Clemastine improves axonal hypomyelination via inhibition of <t>p38</t> phosphorylation in microglial cells. Panel a showing phosphorylation-p38 (38 kDa) and total-p38 (38 kDa) immunoreactive bands. Panel b is bar graph which indicates that expression of p-p38 were improved in the AMCs after OGD administration for 1 h. The clemastine and MCC950 may attenuate the increment. Panel c showing IL-1β (17 kDa), NLRP3 (62 kDa), and β-actin (42 kDa) immunoreactive bands. Panels d and e are bar graphs showing the expression of IL-1β and NLRP3 were significantly up-regulated at 1 h after treatment with OGD compared with the controls. Clemastine could reduce the high expressions of NLRP3 and IL-1β proteins by inhibiting the p-p38. The inhibition was strengthened after adding additional MCC950 or <t>SB203580</t> (a specific p38 pathway inhibitor). Panel f showing MBP (32 kDa), CNPase (48 kDa), and β-actin (42 kDa) immunoreactive bands. Panels h and g are bar graphs showing the protein expressions of MBP and CNPase were significantly downregulated at 7 days after OGD compared with the controls. Clemastine and SB203580 could upregulate the expressions of MBP and CNPase proteins induced by OGD by inhibiting the p-p38. When additional MCC950 or SB203580 was added, the expression of MBP was upregulated compared with the OGD + clemastine group. N =3. * P < 0.05
Adezmapimod Hydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adezmapimod hydrochloride/product/MedChemExpress
Average 95 stars, based on 1 article reviews
adezmapimod hydrochloride - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

Image Search Results


Clemastine improves axonal hypomyelination via inhibition of p38 phosphorylation in microglial cells. Panel a showing phosphorylation-p38 (38 kDa) and total-p38 (38 kDa) immunoreactive bands. Panel b is bar graph which indicates that expression of p-p38 were improved in the AMCs after OGD administration for 1 h. The clemastine and MCC950 may attenuate the increment. Panel c showing IL-1β (17 kDa), NLRP3 (62 kDa), and β-actin (42 kDa) immunoreactive bands. Panels d and e are bar graphs showing the expression of IL-1β and NLRP3 were significantly up-regulated at 1 h after treatment with OGD compared with the controls. Clemastine could reduce the high expressions of NLRP3 and IL-1β proteins by inhibiting the p-p38. The inhibition was strengthened after adding additional MCC950 or SB203580 (a specific p38 pathway inhibitor). Panel f showing MBP (32 kDa), CNPase (48 kDa), and β-actin (42 kDa) immunoreactive bands. Panels h and g are bar graphs showing the protein expressions of MBP and CNPase were significantly downregulated at 7 days after OGD compared with the controls. Clemastine and SB203580 could upregulate the expressions of MBP and CNPase proteins induced by OGD by inhibiting the p-p38. When additional MCC950 or SB203580 was added, the expression of MBP was upregulated compared with the OGD + clemastine group. N =3. * P < 0.05

Journal: Journal of Neuroinflammation

Article Title: Clemastine improves hypomyelination in rats with hypoxic–ischemic brain injury by reducing microglia-derived IL-1β via P38 signaling pathway

doi: 10.1186/s12974-019-1662-6

Figure Lengend Snippet: Clemastine improves axonal hypomyelination via inhibition of p38 phosphorylation in microglial cells. Panel a showing phosphorylation-p38 (38 kDa) and total-p38 (38 kDa) immunoreactive bands. Panel b is bar graph which indicates that expression of p-p38 were improved in the AMCs after OGD administration for 1 h. The clemastine and MCC950 may attenuate the increment. Panel c showing IL-1β (17 kDa), NLRP3 (62 kDa), and β-actin (42 kDa) immunoreactive bands. Panels d and e are bar graphs showing the expression of IL-1β and NLRP3 were significantly up-regulated at 1 h after treatment with OGD compared with the controls. Clemastine could reduce the high expressions of NLRP3 and IL-1β proteins by inhibiting the p-p38. The inhibition was strengthened after adding additional MCC950 or SB203580 (a specific p38 pathway inhibitor). Panel f showing MBP (32 kDa), CNPase (48 kDa), and β-actin (42 kDa) immunoreactive bands. Panels h and g are bar graphs showing the protein expressions of MBP and CNPase were significantly downregulated at 7 days after OGD compared with the controls. Clemastine and SB203580 could upregulate the expressions of MBP and CNPase proteins induced by OGD by inhibiting the p-p38. When additional MCC950 or SB203580 was added, the expression of MBP was upregulated compared with the OGD + clemastine group. N =3. * P < 0.05

Article Snippet: To study the effect of clemastine on the p38 signaling pathways under hypoxic condition, microglial cells were divided into six groups: Control group, OGD group, OGD + 20ng/ml clemastine group, OGD + 20ng/ml clemastine + 0.1μM MCC950 group, OGD + 20ng/ml clemastine + 0.5μM SB203580 (p38 MAPK inhibitor, Topscience, Cat. No. T1764), 20ng/ml clemastine group.

Techniques: Inhibition, Phospho-proteomics, Expressing